Prelude Therapeutics logo

Prelude Therapeutics

PRLD | NASDAQ
Chart Builder DCF Calculator
$3.41
-$0.04 (-1.16%)
At close: Nov 16, 2026, 4:00 PM ET
$3.41
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET
-1.16%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
55.5
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #182/1021 (Top 18%)

Key Statistics

Market Data

Market Cap $335.51M
1D Range
3.28 3.46
52W Range
1.35 6.63

Valuation (TTM)

PE -4.32
PB 2.51
EV/EBITDA -3.42

Valuation (NTM)

Forward PE 34.64
Forward PEG 0.06
Price Target $8.00
Loading financial charts...

Profile

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs....

Sector Healthcare
Industry Biotechnology
Employees 79
IPO Date Sep 25, 2020
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Latest Earnings
Nov 16, 2026
EPS
-$0.12
Miss -1300.00%
REV
$5.65M
Miss -80.53%
Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$8.00
Upside
+134.60%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.